#297Extended selection 101–500

TScan Therapeutics

Massachusetts / New England

Cell and gene therapyOncology / ADC / high-potency

Manufacturing profile

Cell and gene therapy
Oncology / ADC / high-potency

Biopharma hub: Massachusetts / New England

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Starting-material and cell-bank control
  2. 2Cell expansion or vector production
  3. 3Purification, concentration and formulation
  4. 4Identity, viability, potency and qPCR
  5. 5Sterility, endotoxin, environmental monitoring and chain of custody
  6. 6Contained dispensing and high-potency handling
  7. 7Chemical synthesis or biologic upstream
  8. 8Purification and formulation
  9. 9HPLC/LC-MS/CE and potency analytics

Relevant FUZKK packages

Lumex — instrumental QC

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology